<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01844804</url>
  </required_header>
  <id_info>
    <org_study_id>B5371001</org_study_id>
    <secondary_id>REFLECTIONS B537-01</secondary_id>
    <nct_id>NCT01844804</nct_id>
  </id_info>
  <brief_title>A Pharmacokinetics Study Comparing PF-06438179 and Infliximab in Healthy Volunteers (REFLECTIONS B537-01)</brief_title>
  <official_title>Phase 1, Double Blind, Randomized, Parallel-Group, Single-Dose, 3-Arm, Comparative Pharmacokinetic Study of PF-06438179 and Infliximab Sourced From US and EU Administered to Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, healthy volunteers will receive a single intravenous dose of either
      PF-06438179 or infliximab (United States) or infliximab (European Union). During the course
      of the study, the pharmacokinetics will be assessed by sampling the levels of drug in the
      blood, and by comparing these levels among the different administration arms of PF-06438179
      and the licensed infliximab products. Safety, tolerability, and immunologic response will
      also be evaluated throughout.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Observed Serum Concentration (Cmax)</measure>
    <time_frame>Day 1 - Day 57</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUCt)</measure>
    <time_frame>Day 1 - Day 57</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve From Time Zero Extrapolated to Infinite Time (AUCinf)</measure>
    <time_frame>Day 1 - Day 57</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Systemic Clearance (CL)</measure>
    <time_frame>Day 1 - Day 57</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Disposition Half-Life (t1/2)</measure>
    <time_frame>Day 1 - Day 57</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Distribution at Steady State (Vss)</measure>
    <time_frame>Day 1 - Day 57</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of anti-infliximab antibodies (ADA), including neutralizing antibodies (Nab)</measure>
    <time_frame>Day 1 - LSLV or Day 85 whichever occurs later</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">146</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>A = PF-06438179</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B = Infliximab-EU</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>C = Infliximab-US</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PF-06438179</intervention_name>
    <description>Single-dose of 10 mg/kg administered as an intravenous infusion in not less than 2 hours on Day 1</description>
    <arm_group_label>A = PF-06438179</arm_group_label>
    <other_name>Infliximab-Pfizer</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Remicade</intervention_name>
    <description>Single-dose of 10 mg/kg administered as an intravenous infusion in not less than 2 hours on Day 1</description>
    <arm_group_label>B = Infliximab-EU</arm_group_label>
    <other_name>Infliximab (European Union)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Remicade</intervention_name>
    <description>Single-dose of 10 mg/kg administered as an intravenous infusion in not less than 2 hours on Day 1</description>
    <arm_group_label>C = Infliximab-US</arm_group_label>
    <other_name>Infliximab (United States)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy female subjects of non-childbearing potential and healthy male subjects
             (healthy is defined as no clinically relevant abnormalities identified by a detailed
             medical history, full physical examination, including blood pressure and pulse rate
             measurement, 12-lead ECG and clinical laboratory tests).

          -  Body Mass Index (BMI) of 17.5 to 32.0 kg/m2; and a total body weight &gt;50kg (110 lbs).

        Exclusion Criteria:

          -  Evidence or history of clinically significant infectious, hematological, renal,
             endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric,
             neurologic, autoimmune, or allergic disease (including drug allergies, but excluding
             untreated, asymptomatic, seasonal allergies at time of dosing).

          -  Previous exposure to a monoclonal antibody, or current use of other biologics.

          -  History of hypersensitivity reaction to inactive components of the study drugs or any
             murine proteins or anaphylactic reactions to therapeutic drugs.

          -  History of tuberculosis (TB) or a positive latent TB test at Screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B5371001&amp;StudyName=A%20Pharmacokinetics%20Study%20Comparing%20PF-06438179%20and%20Infliximab%20in%20Healthy%20Volunteers%20%28REFLECTIONS%20B537-01%29</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 29, 2013</study_first_submitted>
  <study_first_submitted_qc>April 29, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 1, 2013</study_first_posted>
  <last_update_submitted>January 6, 2014</last_update_submitted>
  <last_update_submitted_qc>January 6, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 7, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bioequivalence</keyword>
  <keyword>Biosimilarity</keyword>
  <keyword>Similarity</keyword>
  <keyword>PK</keyword>
  <keyword>Phase 1</keyword>
  <keyword>Infliximab</keyword>
  <keyword>Healthy Volunteers</keyword>
  <keyword>Single-dose</keyword>
  <keyword>Immunology</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infliximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

